延迟广谱革兰阴性菌抗生素与临床结局的关联:经验性抗生素选对有多重要?
基于美国928家医院成人住院患者的回顾性队列,比较经验性窄谱抗生素升级为广谱(延迟广谱治疗,DBT)与经验性广谱抗生素延续(早期广谱治疗,EBT)的临床结局。匹配后DBT组死亡率8.7% vs EBT组9.5%(P=0.022),再入院率10.5% vs 11.8%(P<0.0001),不良药物事件率8.4% vs 7.2%(P<0.0001),DBT临床结局优于EBT(win-ratio 1.06;P<0.0001)。
要点
- 延迟广谱抗生素未与更差结局相关,DBT组死亡率8.7%低于EBT组9.5%(P=0.022)。
- DBT组再入院率10.5%低于EBT组11.8%(P<0.0001),不良药物事件率8.4%高于EBT组7.2%(P<0.0001)。
- 匹配后DBT临床结局优于EBT(win-ratio 1.06;P<0.0001)。
核心结论
- 在最终接受广谱抗生素治疗的大型成人住院患者样本中,平均而言延迟启动广谱抗生素与更差结局无关。
- 该发现挑战了「经验性抗生素宁宽勿窄更安全」的常见观念,尽管经验性广谱治疗无疑有时是必要的。
研究设计与样本
- 回顾性队列研究,纳入美国928家医院的成人住院患者。
- 比较经验性窄谱抗生素升级为广谱(延迟广谱治疗,DBT)与经验性广谱抗生素延续为治疗后(早期广谱治疗,EBT)的临床结局,采用Win Ratios分析。
- DBT与EBT患者按医院、入院诊断及包含28个临床变量的倾向性评分进行匹配。
主要发现
- 共746 880例住院患者,其中82 276例(11%)接受DBT,664 604例(89.0%)接受EBT。
- 67 046例DBT患者与67 046例EBT患者匹配后,DBT组死亡率为8.7%,EBT组为9.5%(P=0.022)。
- DBT组再入院率为10.5%,EBT组为11.8%(P<0.0001)。
- DBT组不良药物事件率为8.4%,EBT组为7.2%(P<0.0001)。
- 匹配患者中,DBT后临床结局优于EBT(win-ratio 1.06;P<0.0001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinicians often start unnecessarily broad-spectrum empiric gram-negative antibiotics out of the concern that delaying effective therapy could lead to a worse clinical outcome. This study examined the consequences of delayed initiation of broad-spectrum gram-negative antibiotics. METHODS: In a retrospective cohort of adult inpatients from 928 US hospitals, we compared clinical outcomes after (1) empiric narrow-spectrum antibiotics escalated to broad-spectrum antibiotics (delayed broad-spectrum therapy [DBT]) and (2) empiric broad-spectrum antibiotics continued as post-empiric therapy (early broad-spectrum therapy [EBT]) using Win Ratios. DBT and EBT patients were matched on hospital, admitting diagnosis, and propensity scores incorporating 28 clinical variables. The outcome of interest was a ranked composite of mortality, readmission, and adverse drug events. RESULTS: Out of 746 880 inpatients, 82 276 (11%) received DBT and 664 604 (89.0%) received EBT. Among the 67 046 with DBT who were matched to 67 046 with EBT, mortality was 8.7% after DBT and 9.5% after EBT (P = .022), readmission was 10.5% after DBT and 11.8% after EBT (P < .0001), and the rate of adverse drug events was 8.4% after DBT and 7.2% after EBT (P < .0001). Among matched patients, clinical outcomes were superior after DBT compared with EBT (win-ratio 1.06; P < .0001). CONCLUSIONS: On average, among a large sample of adult inpatients who ultimately received broad-spectrum antibiotic therapy, delaying initiation of a broad-spectrum antibiotic was not associated with worse outcomes. Although broad-spectrum empiric therapy is undoubtedly sometimes warranted, this finding challenges the common belief that is it safer to err towards overly broad-spectrum empiric antibiotic therapy.
引用
- Baghdadi JD, Goodman KE, Magder LS, et al. Association Between Delayed Broad-Spectrum Gram-negative Antibiotics and Clinical Outcomes: How Much Does Getting It Right With Empiric Antibiotics Matter? Clin Infect Dis. 2025. PMID: 39874272. doi:10.1093/cid/ciaf039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。